INTRODUCTION: Assessing the formation and regression of @entity82 in @entity409 ( @entity409 ) is important. Current methods of assessment employed in clinical practice are inadequate. We present a review of the utility of non-invasive biomarkers of @entity1575 . SOURCES OF DATA: Published material on MEDLINE. AREAS OF AGREEMENT: Liver biopsy is an imperfect 'gold standard'. Biomarkers are excellent at detecting significant @entity82 across different aetiologies of @entity409 . There is growing evidence that they also predict clinical outcomes. AREAS OF CONTROVERSY: Non-invasive biomarkers can be used in clinical practice to screen for significant @entity82 , but the utility of liver biopsy is retained in answering specific questions. Biomarkers cannot be used robustly in clinical trials as doubts remain over their ability to detect small changes in @entity82 , @entity32 and what influences them. AREAS TIMELY FOR DEVELOPING RESEARCH: Community screening and algorithms are being developed with biomarkers to more effectively direct resources. Novel imaging techniques have huge potential advantages, particularly in secondary care for risk stratification.

Non-invasive monitoring of XXXX .

@entity1575 :: ('MESH:D008103', 'Disease') :: ['liver fibrosis'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity409 :: ('MESH:D008107', 'Disease') :: ['CLD', 'chronic liver disease']
@entity1575 :: (MESH:D008103,Disease) :: ['liver fibrosis']
